These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 18711188)
1. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. Manegold C; Gravenor D; Woytowitz D; Mezger J; Hirsh V; Albert G; Al-Adhami M; Readett D; Krieg AM; Leichman CG J Clin Oncol; 2008 Aug; 26(24):3979-86. PubMed ID: 18711188 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. Hirsh V; Paz-Ares L; Boyer M; Rosell R; Middleton G; Eberhardt WE; Szczesna A; Reiterer P; Saleh M; Arrieta O; Bajetta E; Webb RT; Raats J; Benner RJ; Fowst C; Meech SJ; Readett D; Schiller JH J Clin Oncol; 2011 Jul; 29(19):2667-74. PubMed ID: 21632509 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202 [TBL] [Abstract][Full Text] [Related]
4. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966 [TBL] [Abstract][Full Text] [Related]
5. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. Felip E; Rosell R; Maestre JA; Rodríguez-Paniagua JM; Morán T; Astudillo J; Alonso G; Borro JM; González-Larriba JL; Torres A; Camps C; Guijarro R; Isla D; Aguiló R; Alberola V; Padilla J; Sánchez-Palencia A; Sánchez JJ; Hermosilla E; Massuti B; J Clin Oncol; 2010 Jul; 28(19):3138-45. PubMed ID: 20516435 [TBL] [Abstract][Full Text] [Related]
6. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H; J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033 [TBL] [Abstract][Full Text] [Related]
7. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591 [TBL] [Abstract][Full Text] [Related]
8. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153 [TBL] [Abstract][Full Text] [Related]
9. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250 [TBL] [Abstract][Full Text] [Related]
10. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422 [TBL] [Abstract][Full Text] [Related]
11. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646 [TBL] [Abstract][Full Text] [Related]
12. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Belani CP; Fossella F Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485 [TBL] [Abstract][Full Text] [Related]
13. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. Soria JC; Márk Z; Zatloukal P; Szima B; Albert I; Juhász E; Pujol JL; Kozielski J; Baker N; Smethurst D; Hei YJ; Ashkenazi A; Stern H; Amler L; Pan Y; Blackhall F J Clin Oncol; 2011 Nov; 29(33):4442-51. PubMed ID: 22010015 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567 [TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer. Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333 [TBL] [Abstract][Full Text] [Related]
18. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037 [TBL] [Abstract][Full Text] [Related]
19. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811 [TBL] [Abstract][Full Text] [Related]
20. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]